Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen downgraded shares of Keros Therapeutics (NASDAQ:KROS) from a sell rating to a strong sell rating in a research note published on Sunday morning.

A number of other research firms have also weighed in on KROS. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th. Zacks Research cut Keros Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday. Wells Fargo & Company reduced their target price on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 4th. Finally, Leerink Partners decreased their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.50.

Keros Therapeutics Stock Performance

KROS stock opened at $10.10 on Friday. Keros Therapeutics has a one year low of $9.69 and a one year high of $22.55. The company’s fifty day moving average price is $10.63 and its 200-day moving average price is $12.05. The company has a market capitalization of $200.28 million, a PE ratio of -2.73 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, research analysts predict that Keros Therapeutics will post -5.16 EPS for the current fiscal year.

Insider Activity

In related news, Director Nima Farzan sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the transaction, the director owned 9,767 shares of the company’s stock, valued at $104,799.91. This represents a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the transaction, the director owned 9,767 shares in the company, valued at $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,425 shares of company stock valued at $89,994. Corporate insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Financial Management Professionals Inc. bought a new position in shares of Keros Therapeutics during the 4th quarter worth $29,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Keros Therapeutics in the second quarter valued at about $90,000. Finally, PDT Partners LLC purchased a new stake in Keros Therapeutics in the second quarter worth about $122,000. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.